Vericel Corporation (NASDAQ: VCEL) shares plummeted 5.11% in the intraday trading session on Thursday, despite the company reporting better-than-expected earnings for the fourth quarter of 2024.
The biopharmaceutical company reported quarterly earnings of $0.38 per share, surpassing the analyst consensus estimate of $0.32 by 18.75%. However, Vericel's quarterly sales of $75.38 million missed the analyst consensus estimate of $76.47 million by 1.43%, which may have contributed to the stock's decline.
While Vericel's earnings exceeded expectations, the company's sales miss suggests that its revenue growth may have fallen short of analysts' projections. Investors often closely monitor a company's revenue performance as it can be an indicator of future earnings potential and growth prospects.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。